Beta-caryophyllene is a common and often abundant terpene found in cannabis. Its distinctive flavor contributes to the spiciness of black pepper and can be found in high amounts in cloves, hops, and rosemary. It falls under the FDA’s “generally recognized as safe” classification, so large doses can be safely consumed.
Over the last decade, β-caryophyllene has gained the attention of scientists when it was discovered to be one of the first non-cannabinoids to directly activate cannabinoid receptors. Beta-caryophyllene-rich cannabis strains may therefore have specific medicinal effects due to this terpene’s effect on our endocannabinoid system.
CB2 receptors are found in immune tissues throughout the body and are increased in the brain in disease or following injury. Their activation reduces inflammation, which lessens pain and reduces the damaging consequences that chronic inflammation has on brain function and risk for developing brain diseases.
Research on β-caryophyllene is somewhat limited. On one hand, it’s tempting to generalize the therapeutic benefits of β-caryophyllene based on the effects of other compounds that activate CB2 receptors. After all, CB2 receptor activation by other compounds can play an important role in reducing pain, preventing seizures, and even decreasing plaque buildup in the arteries.
But not all activators of CB2 receptors have the same effect. Differences in the specific way that β-caryophyllene activates CB2 receptors can lead to differences in the strength of therapeutic effects.
The data suggest that, in many cases, β-caryophyllene can provide pain relief. In one study, scientists injected mice with β-caryophyllene and found that they experienced less pain than those treated with the control solution. Furthermore, β-caryophyllene enhanced the pain-reducing strength of low-dose morphine. This could be one reason why those using prescription opioids from pain are often able to decrease their dose of opioids when they begin using medical cannabis.
There are numerous inflammatory diseases that affect the digestive tract. Colitis is one such disease where inflammation of the intestines causes pain, diarrhea, abdominal cramping, and even increases risk for cancer. In mice that were experimentally given colitis, treatment with β-caryophyllene helped by decreasing inflammation in the colon.
The activation of CB2 receptors by β-caryophyllene certainly plays a role in its anti-pain effects, but it also contributes to its ability to protect the bodyand brain from disease. For instance, brain inflammation plays a substantial role in the onset and progression of Alzheimer’s disease. In a mouse modelof Alzheimer’s disease, β-caryophyllene activated CB2 and PPAR-γ receptors and reduced hallmark features of Alzheimer’s such as the accumulation of brain plaques. These actions also protect against the cognitive decline that characterizes this model of disease.
Indicas vs. Sativas: Which Has More β-Caryophyllene?
There is no clear evidence that cannabis labelled as indica or sativa in the commercial marketplace have significantly more β-caryophyllene than the other. Laboratory testing data indicates that knowing whether a strain is an indica, sativa, or hybrid is not a reliable indicator of whether it will have low, medium, or high levels of this terpene.
Which Cannabis Strains Tend to Have the Most β-Caryophyllene?
Strains with high levels of β-caryophyllene span the cannabis spectrum. It tends to be an abundant terpene in indicas like Death Star and Sour Bubble, sativas such as Candyland and Lemon G, and the hybrid strains GSC and Moon Cookies. Death Star is often especially rich in β-caryophyllene.
Find These Strains Near You:
- Death Star
- Sour Bubble
- Moon Cookies
- Cookies and Cream
- Blueberry Cheesecake
- Lemon G
- White Widow
Some strains have have highly similar terpene profiles, even when one is an indica and one is a sativa. Take the strains Death Star (indica) and Candyland (sativa) as examples. They have highly similar terpene profiles even though one is an indica and the other sativa, suggesting that the effects they have on you may not be very different compared to strains with a more distinct terpene profile. Lemon G, for example, tends to also be high in β-caryophyllene levels but has an overall terpene profile quite different from Death Star or Candyland.
This is why knowing the indica/sativa designation of a strain may not be a good indicator of the key ingredients it contains, and therefore the effects it will provide. You need to know the full, lab-tested cannabinoid and terpene profile of a strain or product (which usually isn’t available to consumers).
Finding Strains High in β-Caryophyllene
When selecting a strain that tends to be high in β-caryophyllene, keep in mind that individual products may or may not be representative of that strain’s true composition, and most product labels do not currently provide terpene profiles to consumers. Do your research, and ask a knowledgeable retailer to recommend brands with a reputation for quality.
Even though many states do not require cannabis products to have their terpene profiles measured and labelled, some conscientious and forward-thinking brands take the extra step of having terpene profiles measured and provide these to consumers on packaging. One of the best things you can do as a consumer is ask your dispensaries to carry products with labelled terpene profiles, and use your purchasing power to reward brands that make this crucial information accessible.
Being able to shop for cannabis products with verified terpene profiles will be very important for consumers, since terpenes like β-caryophyllene may offer specific therapeutic benefits for some people. But we still have a lot to learn about this cannabis terpene.
The Future of β-Caryophyllene Research
One of the biggest questions regarding the role that cannabis terpenes play in a strain’s therapeutic benefits is whether they’re expressed in sufficient concentrations to have an effect on the body. The available scientific studies have used isolated β-caryophyllene, often in high doses. Are these doses substantially higher than what can be consumed with a β-caryophyllene-rich cannabis strain? At this point, it’s unclear.
The future of β-caryophyllene research (and all cannabis terpenes) should involve studying the terpene at doses consistent with typical human consumption as well as in the presence of other cannabinoids. This could be done by systematically altering levels of a terpene while keeping levels of other cannabis compounds constant. Nonetheless, because β-caryophyllene can be added safely added to food, many products could experiment with boosting β-caryophyllene levels to therapeutically-relevant doses.